AzTrials
AzTrials

Chronic PainREPERADONCT04467229

Early Detection of Mental Disorders in Adolescents With Chronic Pain: Creation of a Screening Tool for Use by the General Practitioner

A study testing Focus group in people with Chronic Pain and Mental Disorder, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This research aims to create a tool for detection of mental health disorders in adolescents with chronic pain. The first part is testing a screening questionnaire and comparing in with existing questionnaires. Read more about this study

Who is it for?
Ages 10 to 18 years
Conditions the study is for
Chronic Pain, Mental Disorder
What is being tested?
Focus group
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteFrance
Study dates
6 Jul 2020to 30 Sep 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 10 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • patient from 10 to 18 years old
  • chronic pain (existing for more than 3 months or longer than tissue repair time)
  • first consultation in the service
  • Collection of the written consent of the holders of parental authority and agreement of the adolescent
  • Adolescents able to understand the questionnaire and the purpose of the study
  • Affiliation to a social security scheme or beneficiary

Who cannot join

  • Decompensated physical or psychological pathology requiring urgent medical treatment
  • Heavy psychological pathology preventing the adolescent's understanding of the study
  • Patient benefiting from State Medical Aid

Trial locations and contacts

1 site in 1 country.

Alexandra LOISEL, PH contact

01 71 73 85 47

loisel.alexandra@aphp.fr

Barbara TOURNIAIRE, ph contact

01 71 73 89 19

barbara.tourniaire@aphp.fr

France1 site
  • Centre de la douleur et de la migraine-Hôpital Trousseau

    Paris, 75012

    Alexandra LOISEL, PH, 01 71 73 85 47, loisel.alexandra@aphp.fr

    Barbara TOURNIAIRE, PH, 01 71 73 89 19, barbara.tourniaire@aphp.fr

Other trials in France

About this study

This research aims to create a tool for detection of mental health disorders in adolescents with chronic pain. The first part is testing a screening questionnaire and comparing in with existing questionnaires. The second part involves two focus group with the adolescents aimed at recording their perception of the questionnaire.

Read the detailed description

First part : creation of a screening tool. After detailed interviews with chronic pain experts and bibliographic research, a screening tool for mental disorders in chronically painful adolescents has been designed for use by the general practitioner. This tool is composed of 10 questions, making up a score of 10 points. The tool will be compared to two screening tools used in different clinical contexts, the HAD scale and the RPPS scale, in order to determine a positivity threshold. There is only one center participating in the research, the Centre de la Douleur et de la migraine de l'hôpital Trousseau (Trousseau Hospital Pain Center). Parents' consent is required for participation. For this assessment, the adolescents (between 10 and 18 years old) that see a doctor at the Centre de la douleur, will be asked to fill up the questionnaires in the waiting room. The filling of the questionnaire takes a few minutes. At the end of the appointment, the doctor will read the questionnaire to check that all elements have been addressed during the appointment.

Second part : focus group on the questionnaire: 5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the Centre de la Douleur de Trousseau. Two groups will be organized, the length of the group discussion being one hour. These focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. The group will undergo full transcription. The verbatim will be anonymous and will be analysed through qualitative methods.

The data will help designing a guidebook for the clinician explaining the main points in screening for mental disorders in chronic pain adolescent patients.

A validation study for the screening tool will be eventually carried out after the completion of this preliminary study.

Being tested
Focus group
Keywords
Chronic Pain, Mental Disorders
Medical subject headings
Chronic Pain, Mental Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Focus groupBehavioural

    5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the Centre de la Douleur de Trousseau. Two groups will be organized, the length of the group discussion being one hour. These focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. The group will undergo full transcription. The verbatim will be anonymous and will be analysed through qualitative methods.

Study groups in NCT04467229
Study groupRoleWhat they receive
Focus group with chronically painful adolescentsExperimentalAdolescents with chronic pain
Receives: Behavioral: Focus group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Screening questionnaire score

    A new Screening questionnaire elaborated beforehand by the study will be answered by patients in order to detect psychological suffering in chronically painful adolescents The screening questionnaire consists in 10 items (yes/no response format)

    Measured: Baseline visit

Secondary outcomes (3)
  1. Hospital Anxiety and Depression (HAD) score

    Patients complete a Hospital Anxiety and Depression (HAD) scale questionnaire

    Measured: Baseline visit

  2. Pediatric Pain Screening Tool (PPST) score

    Patients complete a Pediatric Pain Screening Tool questionnaire

    Measured: Baseline visit

  3. Participants feedback

    Focus group questions will provide descriptions of patients' experiences with the questionnaire

    Measured: up to 3 months upon recuitment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jul 2020
  2. Study start6 Jul 2020 (estimated)
  3. Primary completion30 Sep 2020 (estimated)
  4. Study completion30 Sep 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04467229
Sponsor's protocol ID
APHP200623
Acronym
REPERADO
Status last verified
Jul 2020
First submitted
25 May 2020
Last updated
10 Jul 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Focus group in people with Chronic Pain and Mental Disorder, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Alexandra LOISEL, PH (01 71 73 85 47, loisel.alexandra@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Screening questionnaire score (time frame: Baseline visit). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
REPERADO Clinical Trial NCT04467229 | AzTrials